| COVID-19 |
1 |
1 |
| Canada |
0 |
0.49 |
| Polymerase Chain Reaction |
0 |
0.49 |
| Severe Acute Respiratory Syndrome |
0 |
0.49 |
| Acute Respiratory Distress Syndrome |
0 |
0.4 |
| Antigens |
0 |
0.33 |
| Biologic Therapy |
0 |
0.27 |
| Bacteria |
0 |
0.16 |
| Grant |
0 |
0.16 |
| Hospital |
0 |
0.16 |
| Intellectual Property |
0 |
0.16 |
| Jobs |
0 |
0.16 |
| Office Visits |
0 |
0.16 |
| Pandemic |
0 |
0.16 |
| Pharmacogenomics |
0 |
0.16 |
| Point-of-Care |
0 |
0.16 |
| Viral Load |
0 |
0.16 |
| Genomic Medicine |
0 |
0.13 |
| Medical Life |
0 |
0.13 |